Clinical Trial Update: Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a three-drug combination (acalabrutinib, venetoclax, and durvalumab) for Richter transformation arising from chronic lymphoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Richter Syndrome
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Durvalumab (durvalumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Mayo Clinic | Conditions: Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 2 | Status: RECRUITING